Louise Herbild

Do guidelines recommending pharmacogenetic testing of psychiatric patients affect treatment costs and the use of healthcare services?

T. Werge, D. Gyrd-Hansen, M. Bech, 2011, Scandinavian journal of public health.

Does Pharmacogenetic Testing for CYP450 2D6 and 2C19 Among Patients with Diagnoses within the Schizophrenic Spectrum Reduce Treatment Costs?

T. Werge, H. Rasmussen, G. Jürgens, 2013, Basic & clinical pharmacology & toxicology.

Estimating the Danish populations' preferences for pharmacogenetic testing using a discrete choice experiment. The case of treating depression.

Mickael Bech, Dorte Gyrd-Hansen, D. Gyrd-Hansen, 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Mental health of migrants in low-skilled work and the families they leave behind

H. Rasmussen, G. Jürgens, Louise Herbild, 2016 .

Patient preferences for pharmacogenetic screening in depression

D. Gyrd-Hansen, M. Bech, Louise Herbild, 2008, International Journal of Technology Assessment in Health Care.

Does Pharmacogenetic Testing for CYP450 2D6 and 2C19 Among Patients with Diagnoses within the Schizophrenic Spectrum Reduce Treatment Costs?

T. Werge, H. Rasmussen, G. Jürgens, 2013, Basic & clinical pharmacology & toxicology.